News Headlines Article

OIG: Soaring Medicaid Brand-name Drug Prices Offset by Rebates
Health Leaders Media

The costs of Medicaid’s brand-name drugs grew at about three times the rate of inflation from 2005-2010, but that increase was offset by rebates to state programs, a federal audit shows.

The report from the Department of Health and Human Services Office of Inspector General found that brand-name drug payments by state Medicaid programs grew between 34% and 40% for the five year period, while overall inflation grew only 13%.